Heather Bresch had a rough day yesterday. The CEO of Mylan NV, the maker of the much-in-the-news EpiPen allergy shot, was grilled by the House Oversight and Government Reform Committee, Bloomberg reports. Committee members played hardball, questioning Bresch’s ethics and wondering just why she’s worth $19 million a year. At the center of it all: the $600 price for a two-pack of EpiPen, yet one more example of the public’s growing dismay over the cost of new therapies.
“Jason Chaffetz, a Utah Republican, accused Bresch and Mylan of downplaying its profits while at the same time paying its senior executives hundreds of millions of dollars,” Bloomberg reports.
Both political parties piled on. Chaffetz “was followed by Maryland Representative Elijah Cummings, the panel’s top Democrat, who accused the drugmaker of taking advantage of the U.S. health-care system.”
Source: Bloomberg
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.